A Phase 2 study of TQB3616 and Fulvestrant in advanced breast cancer

Study Description

A study evaluating the efficacy and safety of TQB3616 capsules combined with Fulvestrant injection in patients with hormone receptor-positive and HER2-negative advanced or metastatic breast cancer

Study Details

Registry ID:

NCT04796623

Conditions:

HR-positive, HER2-negative Advanced Breast Cancer

Phase:

Phase 2

Target Enrollment:

122 participants

Start Date:

February 4, 2021

Healthy Volunteers:

No

Study Locations (22 sites)

• Affiliated Tumor Hospital of Xinjiang Medical University
  Urumqi, XinjiangChina, China
• Gansu Provincial Hostipal
  Lanzhou, GansuChina, China
• Chongqing University Cancer Hospital
  Chongqing, Chongqing MunicipalityChina, China
• Guangxi Medical University Affiliated Tumor Hospital
  Nanning, GuangxiChina, China
• Chongqing University Cancer Hospital
  Chongqing, ChongqingChina, China
• The First Affiliated Hospital of Xi'an Jiao Tong University
  Xi'an, ShanxiChina, China
• The Second Affiliated Hospital of PLA Air Force Military Medical University
  Xi'an, ShanxiChina, China
• Guangdong General Hospital
  Guangzhou, GuangdongChina, China
• Sun Yat-sen University Cancer Center
  Guangzhou, GuangdongChina, China
• Hunan Cancer Hospital
  Changsha, HunanChina, China
• The First Affiliated Hospital of Xi'an Jiao Tong University
  Xi’an, ShanxiChina, China
• The Second Affiliated Hospital of PLA Air Force Military Medical University
  Xi’an, ShanxiChina, China
• The Fourth Hospital of Hebei Medical University
  Shijiazhuang, HebeiChina, China
• Jiangsu Province Hospital
  Nanjing, JiangsuChina, China
• The Fifth Medical Center of PLA General Hospital
  Beijing, BeijingChina, China
• The Fifth Medical Center of PLA General Hospital
  Beijing, Beijing MunicipalityChina, China
• The First Affiliated Hospital Zhejiang University School of Medicine
  Hangzhou, ZhejiangChina, China
• Shanghai East Hospital
  Shanghai, Shanghai MunicipalityChina, China
• Shanghai East Hospital
  Shanghai, ShanghaiChina, China
• The Second Hospital of Dalian Medical University
  Dalian, LiaoningChina, China
• Liaoning Cancer Hospital & Institute
  Shenyang, LiaoningChina, China
• Harbin Medical University Affiliated Cancer Hospital
  Harbin, HeilongjiangChina, China

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →